Catalyst Biosciences Inc
NASDAQ:CBIO 4:00:00 PM EDT
Products
Catalyst Biosciences Receives FDA Fast Track Designation For Subcutaneous Marzaa For The Treatment Of Episodic Bleeding In Hemophilia A Or B
Published: 12/02/2020 13:25 GMT
Catalyst Biosciences Inc (CBIO) - Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous Marzaa for the Treatment of Episodic Bleeding in Hemophilia a Or B With Inhibitors.
Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous Marzaa for the Treatment of Episodic Bleeding in Hemophilia a Or B With Inhibitors.
Catalyst - Marzaa for Treatment of Episodic Bleeding in Subjects With Hemophilia a Or B With Inhibitors Will Enter Phase 3 Study Crimson 1 This Month.
Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous Marzaa for the Treatment of Episodic Bleeding in Hemophilia a Or B With Inhibitors.
Catalyst - Marzaa for Treatment of Episodic Bleeding in Subjects With Hemophilia a Or B With Inhibitors Will Enter Phase 3 Study Crimson 1 This Month.